Milestone Pharmaceuticals Long Term Debt

Milestone Pharmaceuticals (MIST) currently reports a long-term debt of $140M as of March 2026. That compares with $55M in the prior-year period — up 148.3% year over year. Use the charts on this page to explore Milestone Pharmaceuticals's long-term debt history and peer comparisons.

Milestone Pharmaceuticals's long-term debt increased from $55M to $140M — a 148.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Milestone Pharmaceuticals reported $140M in long-term debt as of March 2026. That compares with $55M in the prior-year period — up 148.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Milestone Pharmaceuticals, and consider following MIST for alerts when major investors trade the stock.

Milestone Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $140M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MIST with unrelated industries.